The cell-penetrating peptide octa-arginine is a potent inhibitor of proteasome activities

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 72, Issue 1, 2009, Pages 219-225

  Kloß, Alexander ^a   Henklein, Peter ^a   Siele, Dagmar ^a   Schmolke, Marion ^b   Apcher, Sébastien ^c   Kuehn, Lothar ^d   Sheppard, Paul W ^e   Dahlmann, Burkhardt ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF MÜNSTER   (Germany)

^c INSERM   (France)

^d LEIBNIZ CENTER FOR DIABETES RESEARCH AT HEINRICH HEINE UNIVERSITY DÜSSELDORF   (Germany)

^e BIOMOL International LP   (United Kingdom)

Author keywords

Cell penetrating peptides; HeLa cells; Inhibitor; Octa arginine; Proteasome; Ubiquitin conjugated proteins

Indexed keywords

CASPASE; CELL PENETRATING PEPTIDE; CHYMOTRYPSIN; OCTA ARGININE PEPTIDE; PROTEASOME; PROTEASOME INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; CELL MEMBRANE PERMEABILITY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG PENETRATION; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC 50; PROTEIN DEGRADATION;

ANIMALS; CHEMISTRY, PHARMACEUTICAL; DRUG CARRIERS; DRUG DESIGN; ERYTHROCYTES; HELA CELLS; HUMANS; MUSCLE, SKELETAL; OLIGOPEPTIDES; PEPTIDES; PROTEASOME ENDOPEPTIDASE COMPLEX; RATS; TECHNOLOGY, PHARMACEUTICAL; UBIQUITIN;

EID: 62949248272     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejpb.2008.10.016     Document Type: Article

References (54)

1. Foerg C., and Merkle H.P. On the biomedical promise of cell penetrating peptides: limits versus prospects. J. Pharm. Sci. 97 (2008) 144-162
2. Patel L.N., Zaro J.L., and Shen W.C. Cell penetrating peptides: intracellular pathways and pharmaceutical perspectives. Pharm Res. 24 (2007) 1977-1992
3. Vives E., Brodin P., and Lebleu B. A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J. Biol. Chem. 272 (1997) 16010-16017
4. Noguchi H., Matsushita M., Okitsu T., Moriwaki A., Tomizawa K., Kang S., Li S.T., Kobayashi N., Matsumoto S., Tanaka K., Tanaka N., and Matsui H. A new cell-permeable peptide allows successful allogeneic islet transplantation in mice. Nat Med. 10 (2004) 305-309
5. Nakase I., Tadokoro A., Kawabata N., Takeuchi T., Katoh H., Hiramoto K., Negishi M., Nomizu M., Sugiura Y., and Futaki S. Interaction of arginine-rich peptides with membrane-associated proteoglycans is crucial for induction of actin organization and macropinocytosis. Biochemistry 46 (2007) 492-501
6. Zaro J.L., and Shen W.C. Quantitative comparison of membrane transduction and endocytosis of oligopeptides. Biochem. Biophys. Res. Commun. 307 (2003) 241-247
7. Al-Taei S., Penning N.A., Simpson J.C., Futaki S., Takeuchi T., Nakase I., and Jones A.T. Intracellular traffic and fate of protein transduction domains HIV-1 TAT peptide and octaarginine. Implications for their utilization as drug delivery vectors. Bioconjugate Chem. 17 (2006) 90-100
8. Zaro J.L., Rajapaksa T.E., Okamoto C.T., and Shen W.C. Membrane transduction of oligoarginine in HeLa cells is not mediated by macropinocytosis. Mol. Pharm. 3 (2006) 181-186
9. Zaro J.L., and Shen W.C. Evidence that membrane transduction of oligoarginine does not require vesicle formation. Exp. Cell Res. 307 (2005) 164-173
10. Kacprzak M.M., Peinado J.R., Than M.E., Appel J., Henrich S., Lipkind G., Houghten R.A., Bode W., and Lindberg I. Inhibition of furin by polyarginine-containing peptides: nanomolar inhibition by nona-d-arginine. J. Biol. Chem. 279 (2004) 36788-36794
11. Cameron A., Appel J., Houghten R.A., and Lindberg I. Polyarginines are potent furin inhibitors. J. Biol. Chem. 275 (2000) 36741-36749
12. Horn M., Pavlik M., Doleckova L., Baudys M., and Mares M. Arginine-based structures are specific inhibitors of cathepsin C. Application of peptide combinatorial libraries. Eur. J. Biochem. 267 (2000) 3330-3336
13. Kown M.H., Yamaguchi A., Jahncke C.L., Miniati D., Murata S., Grunenfelder J., Koransky M.L., Rothbard J.B., and Robbins R.C. l-arginine polymers inhibit the development of vein graft neointimal hyperplasia. J. Thorac. Cardiovasc. Surg. 121 (2001) 971-980
14. Kibler K.V., Miyazato A., Yedavalli V.S., Dayton A.I., Jacobs B.L., Dapolito G., Kim S.J., and Jeang K.T. Polyarginine inhibits gp160 processing by furin and suppresses productive human immunodeficiency virus type 1 infection. J. Biol. Chem. 279 (2004) 49055-49063
15. Glickman M.H., and Ciechanover A. The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol. Rev. 82 (2002) 373-428
16. Bao J., Sato K., Li M., Gao Y., Abid R., Aird W., Simons M., and Post M.J. PR-39 and PR-11 peptides inhibit ischemia-reperfusion injury by blocking proteasome-mediated I kappa B alpha degradation. Am. J. Physiol. Heart Circ. Physiol. 281 (2001) H2612-2618
17. Gao Y., Lecker S., Post M.J., Hietaranta A.J., Li J., Volk R., Li M., Sato K., Saluja A.K., Steer M.L., Goldberg A.L., and Simons M. Inhibition of ubiquitin-proteasome pathway-mediated I kappa B alpha degradation by a naturally occurring antibacterial peptide. J. Clin. Invest. 106 (2000) 439-448
18. Zanetti M., Gennaro R., and Romeo D. Cathelicidins: a novel protein family with a common proregion and a variable C-terminal antimicrobial domain. FEBS Lett. 374 (1995) 1-5
19. Gaczynska M., Osmulski P.A., Gao Y., Post M.J., and Simons M. Proline- and arginine-rich peptides constitute a novel class of allosteric inhibitors of proteasome activity. Biochemistry 42 (2003) 8663-8670
20. Dahlmann B., Ruppert T., Kuehn L., Merforth S., and Kloetzel P.M. Different proteasome subtypes in a single tissue exhibit different enzymatic properties. J. Mol. Biol. 303 (2000) 643-653
21. Kopp F., Dahlmann B., and Kuehn L. Reconstitution of hybrid proteasomes from purified PA700-20 S complexes and PA28alphabeta activator: ultrastructure and peptidase activities. J. Mol. Biol. 313 (2001) 465-471
22. Kuehn L., and Dahlmann B. Reconstitution of proteasome activator PA28 from isolated subunits: optimal activity is associated with an alpha,beta-heteromultimer. FEBS Lett. 394 (1996) 183-186
23. Dahlmann B., Kuehn L., and Reinauer H. Studies on the activation by ATP of the 26 S proteasome complex from rat skeletal muscle. Biochem. J. 309 (1995) 195-202
24. Eisenthal R., and Cornish-Bowden A. The direct linear plot. A new graphical procedure for estimating enzyme kinetic parameters. Biochem. J. 139 (1974) 715-720
25. Futaki S., Suzuki T., Ohashi W., Yagami T., Tanaka S., Ueda K., and Sugiura Y. Arginine-rich peptides. An abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery. J. Biol. Chem. 276 (2001) 5836-5840
26. Suzuki T., Futaki S., Niwa M., Tanaka S., Ueda K., and Sugiura Y. Possible existence of common internalization mechanisms among arginine-rich peptides. J. Biol. Chem. 277 (2002) 2437-2443
27. Tawa Jr. N.E., Odessey R., and Goldberg A.L. Inhibitors of the proteasome reduce the accelerated proteolysis in atrophying rat skeletal muscles. J. Clin. Invest. 100 (1997) 197-203
28. McMartin C., Hutchinson L.E., Hyde R., and Peters G.E. Analysis of structural requirements for the absorption of drugs and macromolecules from the nasal cavity. J. Pharm. Sci. 76 (1987) 535-540
29. Frankel A.D., and Pabo C.O. Cellular uptake of the tat protein from human immunodeficiency virus. Cell 55 (1988) 1189-1193
30. Green M., and Loewenstein P.M. Autonomous functional domains of chemically synthesized human immunodeficiency virus tat trans-activator protein. Cell 55 (1988) 1179-1188
31. Mi Z., Mai J., Lu X., and Robbins P.D. Characterization of a class of cationic peptides able to facilitate efficient protein transduction in vitro and in vivo. Mol. Ther. 2 (2000) 339-347
32. Miyamoto M., Natsume H., Iwata S., Ohtake K., Yamaguchi M., Kobayashi D., Sugibayashi K., Yamashina M., and Morimoto Y. Improved nasal absorption of drugs using poly-l-arginine: effects of concentration and molecular weight of poly-l-arginine on the nasal absorption of fluorescein isothiocyanate-dextran in rats. Eur. J. Pharm. Biopharm. 52 (2001) 21-30
33. Jarver P., Langel K., El-Andaloussi S., and Langel U. Applications of cell-penetrating peptides in regulation of gene expression. Biochem. Soc. Trans. 35 (2007) 770-774
34. Kisselev A.F., Kaganovich D., and Goldberg A.L. Binding of hydrophobic peptides to several non-catalytic sites promotes peptide hydrolysis by all active sites of 20 S proteasomes. Evidence for peptide-induced channel opening in the alpha-rings. J. Biol. Chem. 277 (2002) 22260-22270
35. Mai J.C., Shen H., Watkins S.C., Cheng T., and Robbins P.D. Efficiency of protein transduction is cell type-dependent and is enhanced by dextran sulfate. J. Biol. Chem. 277 (2002) 30208-30218
36. Mitchell D.J., Kim D.T., Steinman L., Fathman C.G., and Rothbard J.B. Polyarginine enters cells more efficiently than other polycationic homopolymers. J. Pept. Res. 56 (2000) 318-325
37. Bochtler M., Ditzel L., Groll M., Hartmann C., and Huber R. The proteasome. Annu. Rev. Biophys. Biomol. Struct. 28 (1999) 295-317
38. Groll M., Bajorek M., Kohler A., Moroder L., Rubin D.M., Huber R., Glickman M.H., and Finley D. A gated channel into the proteasome core particle. Nat. Struct. Biol. 7 (2000) 1062-1067
39. Osmulski P.A., and Gaczynska M. Nanoenzymology of the 20S proteasome: proteasomal actions are controlled by the allosteric transition. Biochemistry 41 (2002) 7047-7053
40. Kisselev A.F., Akopian T.N., Castillo V., and Goldberg A.L. Proteasome active sites allosterically regulate each other, suggesting a cyclical bite-chew mechanism for protein breakdown. Mol. Cell 4 (1999) 395-402
41. Myung J., Kim K.B., Lindsten K., Dantuma N.P., and Crews C.M. Lack of proteasome active site allostery as revealed by subunit-specific inhibitors. Mol. Cell 7 (2001) 411-420
42. Papapostolou D., Coux O., and Reboud-Ravaux M. Regulation of the 26S proteasome activities by peptides mimicking cleavage products. Biochem. Biophys. Res. Commun. 295 (2002) 1090-1095
43. Apcher G.S., Heink S., Zantopf D., Kloetzel P.M., Schmid H.P., Mayer R.J., and Kruger E. Human immunodeficiency virus-1 Tat protein interacts with distinct proteasomal alpha and beta subunits. FEBS Lett. 553 (2003) 200-204
44. Huang X., Seifert U., Salzmann U., Henklein P., Preissner R., Henke W., Sijts A.J., Kloetzel P.M., and Dubiel W. The RTP site shared by the HIV-1 Tat protein and the 11S regulator subunit alpha is crucial for their effects on proteasome function including antigen processing. J. Mol. Biol. 323 (2002) 771-782
45. Seeger M., Ferrell K., Frank R., and Dubiel W. HIV-1 tat inhibits the 20 S proteasome and its 11 S regulator-mediated activation. J. Biol. Chem. 272 (1997) 8145-8148
46. Tanahashi N., Murakami Y., Minami Y., Shimbara N., Hendil K.B., and Tanaka K. Hybrid proteasomes. Induction by interferon-gamma and contribution to ATP-dependent proteolysis. J. Biol. Chem. 275 (2000) 14336-14345
47. Kisselev A.F., and Goldberg A.L. Monitoring activity and inhibition of 26S proteasomes with fluorogenic peptide substrates. Methods Enzymol. 398 (2005) 364-378
48. Fischer R., Bachle D., Fotin-Mleczek M., Jung G., Kalbacher H., and Brock R. A targeted protease substrate for a quantitative determination of protease activities in the endolysosomal pathway. Chembiochem 7 (2006) 1428-1434
49. Futaki S. Oligoarginine vectors for intracellular delivery: design and cellular-uptake mechanisms. Biopolymers 84 (2006) 241-249
50. Futaki S., Nakase I., Tadokoro A., Takeuchi T., and Jones A.T. Arginine-rich peptides and their internalization mechanisms. Biochem. Soc. Trans. 35 (2007) 784-787
51. Zaro J.L., and Shen W.C. Cytosolic delivery of a p16-peptide oligoarginine conjugate for inhibiting proliferation of MCF7 cells. J. Control Release 108 (2005) 409-417
52. Fischer P.M. Cellular uptake mechanisms and potential therapeutic utility of peptidic cell delivery vectors: progress 2001-2006. Med. Res. Rev. 27 (2007) 755-795
53. Meiners S., Ludwig A., Stangl V., and Stangl K. Proteasome inhibitors: poisons and remedies. Med. Res. Rev. (2007)
54. Ludwig H., Khayat D., Giaccone G., and Facon T. Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies. Cancer 104 (2005) 1794-1807